Imatinib Farmoz (Imatinib)

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR tyrosine kinases, making it useful in several hematologic and solid‑tumor indications.

• Chronic myeloid leukemia (CML): improves hematologic, cytogenetic and molecular responses, slowing disease progression.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy.
• Gastrointestinal stromal tumor (GIST): reduces tumor growth and prolongs progression‑free survival.

• Imatinib binds competitively to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This inhibition blocks signaling pathways that drive uncontrolled cell proliferation, survival and migration, leading to apoptosis of malignant cells that depend on these kinases for growth.

Adverse reactions may vary in frequency and severity. Patients should be monitored regularly for any new symptoms.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the lower limbs.
• Muscle cramps: intermittent, may affect daily activities.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools, usually self‑limiting.
• Rash: mild skin irritation.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Severe neutropenia: marked reduction in white blood cells.
• Cardiac failure: signs of reduced cardiac output.
• Pulmonary hypertension: shortness of breath and elevated pulmonary pressure.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Tumor lysis syndrome: metabolic disturbances from rapid tumor breakdown.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks.

• Monitor blood counts: perform regular CBC to detect cytopenias.
• Assess liver function: check transaminases and bilirubin periodically.
• Evaluate cardiac status: baseline ECG and echocardiogram for patients with cardiac history.
• Avoid in pregnancy: drug is classified as Category D; contraindicated unless benefits outweigh risks.
• Use caution in renal impairment: dose adjustment may be required.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Imatinib may interact with other medicines that affect its metabolism or cardiac conduction.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels.
• Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Antacids containing aluminum or magnesium: can lower absorption.
• QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of arrhythmia.
• Concomitant use with other tyrosine kinase inhibitors: may amplify toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, monitor INR.
• Digoxin: possible increase in serum concentration.
• CYP2C8 substrates (e.g., paclitaxel): monitor for enhanced toxicity.
• Statins metabolized by CYP3A4 (e.g., simvastatin): consider dose adjustment.
• Oral contraceptives: reduced effectiveness, advise alternative contraception.